Table 2. Years 1988-2002a summary of experimental FIV vaccines.

Vaccine type Protective efficacy

Conventional vaccines  
Inactivated whole virus Homologous and heterologous protection
Inactivated FIV-infected cells (ICV) Homologous and heterologous protection
Subunit vaccines  
Purified p24 (Gag core) protein No protection
Synthetic Env V3 (variable-3 domain) peptide No protection
Synthetic Env C2 (constant-2 domain) peptide No protection
Baculovirus expressed SU gp100 No protection but a decrease in virus load observed in one study
E. coli expressed SU p100 No protection but a decrease in virus load observed in one study
E. coli expressed SU V3 No protection
Feline herpresvirus-vectored env No protection
Adenovirus-vectored env No protection
Canarypox virus-vectored gag-pol-env (+/- ICV) No protection
DNA vaccines  
Proviral FIVPET DRT DNA (+/- feline IFNg DNA) Some homologous protection but not repeatable
Proviral FIVPPR DVIF Homologous protection
Proviral FIVTM2 DAP1 DNA Homologous protection
Proviral FIVGL8 DRT DNA (+/- feline IL-12 and/or IL-18 DNA) No protection
Proviral FIVGL8 DIN DNA (+/- feline IL-12 and/or IL-18 DNA) Minimal protection against heterologous FIVPET but only decrease in viral load against homologous FIVGL8
FIVZ2 gp140 DNA MIDGE (+/- feline IL-12 DNA MIDGE) Homologous protection
FIVZ2 gp140 DNA MIDGE (+/- feline IL-16 DNA MIDGE) No homologous protection but decrease in viral load
Plasmid pC1-p24 DNA (+/- recombinant SU gp100) No protection

aVaccine trials from 1997 are not included in this table. Results are compiled from references 11 and 12.